Opendata, web and dolomites

AuriMod

From pills to bio-electronics: a wearable anti-inflammatory treatment for prevention of Peripheral Arterial Disease.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "AuriMod" data sheet

The following table provides information about the project.

Coordinator
SZELESTIM GMBH 

Organization address
address: MODECENTERSTRASSE 22/D01
city: WIEN
postcode: 1030
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Austria [AT]
 Project website http://www.szelestim.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-01-01   to  2018-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SZELESTIM GMBH AT (WIEN) coordinator 50˙000.00

Map

 Project objective

Peripheral Arterial Disease (PAD) is a life-threatening disease affecting 200 M people in the world (40.5 M only in EU) and represents the third cause of world cardiovascular morbidity. PAD is a chronic condition generated by the narrowing of arteries, which reduces the normal blood flow and triggers a wide range of manifestations mostly in the lower limbs, from chronic pain to critical limb ischemia. PAD’s progression can lead to chronic wounds, gangrene, amputation, and in most severe cases, death. There is no current solution able to target the broad range of symptoms and complications related to PAD. AuriMod is a wearable device for non-invasive auricular stimulation of the vagus nerve that is capable of treating all symptoms of PAD, avoiding conventional drugs’ side effects and preventing complications including chronic wounds and consequent amputations. Applied to the patient’s ear, AuriMod sends specific electrical stimulation to the auricular branches of the vagus nerve, delivering a patient-tailored therapy that will improve the quality of life of PAD patients. This Phase 1 project will mainly focus on planning further product development, verifying the current supply chain, evaluating the business model and commercialisation plan. The overall innovation project will enable to optimise AuriMod device, conduct clinical trials to validate safety and effectiveness of AuriMod-based therapy and acquire all certifications required for AuriMod’s commercialisation.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "AURIMOD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "AURIMOD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.1.;H2020-EU.2.3.1.)

Leaf Line (2018)

The First Global Ground Station Network to Fully Exploit Microsatellites Data

Read More  

Assist (2015)

Telocate ASSIST – Development and marketing of an acoustic solution for localization and navigation of people in buildings using the smartphone

Read More  

SOFT (2017)

SOFT, the first camera-based colorectal cancer screening test to detect occult blood in faeces immediately and with no lab analysis.

Read More